Skip to main content
Cotinga Pharmaceuticals Inc. logo

Cotinga Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · COT TSXV Manufacturing
Open in API
Filings indexed 7 across all filing types
Latest filing 2020-10-20 Regulatory Filings
Country CA Canada
Listing TSXV COT

About Cotinga Pharmaceuticals Inc.

https://cotingapharma.com/

Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative solutions for reproductive health and comprehensive support for individuals with disabilities. The company leverages proprietary artificial intelligence technologies, including its CHEMSAS platform, to drive the discovery and development of advanced therapeutics. Core activities encompass patient-centric research in areas such as hormonal therapies, fertility preservation techniques, and personalized medicine approaches, aiming to enhance quality of life through tailored treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Cotinga Pharmaceuticals providing an update on the filing status of their annual and interim financial results. It states that the company has not yet filed the audited annual financial statements, management's discussion and analysis for the year ended April 30, 2020, interim financial statements for the period ended July 31, 2020, and related certifications. It also mentions a cease trade order issued by the Ontario Securities Commission due to these missing filings. The document does not contain the actual financial statements or detailed financial data but is an announcement about the delay and status of filings. According to the rules, announcements about report filings or delays without the actual report content should be classified as Regulatory Filings (RNS).
2020-10-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Cotinga Pharmaceuticals providing an update on the filing status of its annual audited financial statements and MD&A for the fiscal year ended April 30, 2020. It mentions the use of a COVID-19 filing extension and the expected filing deadline of October 13, 2020. The document does not contain the actual financial statements or detailed financial data but rather discusses delays and regulatory compliance issues related to the filing. It also references a previous offering and confirms no undisclosed material business developments. The document is short (4866 characters) and serves as an announcement about the status of the annual report filing rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about filing delays and compliance, not the actual Annual Report (10-K) or audited financial statements.
2020-09-30 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a debenture offering by Cotinga Pharmaceuticals. It details the terms of the offering, use of proceeds, and regulatory approvals required. There are no financial statements or detailed financial performance data included. The content focuses on financing activities, specifically a debt issuance and warrants. This matches the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or a report publication notice.
2020-05-08 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis - Quarterly Highlights' for the three and nine months ended January 31, 2020, dated April 1, 2020. It references compliance with Form 51-102F1 and National Instrument 51-102, which are Canadian continuous disclosure requirements. The text includes detailed management discussion on business operations, liquidity, capital resources, forward-looking statements, and risk factors. It explicitly states it is an MD&A for a quarterly period and references unaudited condensed interim financial statements for the same period. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content matches the definition of an Interim / Quarterly Report (IR), which includes substantive financial data and management analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR with high confidence. 9M 2020
2020-04-01 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Cotinga Pharmaceuticals Inc. Condensed Interim Financial Statements Three and Nine Months Ended January 31, 2020' and contains detailed unaudited condensed interim financial statements including statements of financial position, loss and comprehensive loss, cash flows, changes in equity, and notes to the financial statements. The document explicitly states it is prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, and covers a period shorter than a full fiscal year (three and nine months). The presence of substantive financial data and analysis confirms this is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2020
2020-04-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings by the CEO of Cotinga Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2020. The document is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing the actual financial data or substantive financial analysis itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference. The document length is 3028 characters, which is relatively short and consistent with a certification letter rather than a full interim report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-04-01 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.